Business
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric ClinicsNationally recognized founder to become Chief Medical Innovation
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric ClinicsNationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement and evolve the Company's standard of care across the HOPE networkAcquisition would be immediately accretive to revenue and EBITDA for HOPE and NRxMIAMI, Oct. 3, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., (\"HOPE,\" the \"Company\"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of a premier West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, a pioneer and nationally recognized leader in the use of advanced treatments for treatment of CNS disorders, has agreed to join HOPE as Chief Medical Innovation Officer (CMIO).\n\n \n \n \n \n \n \n\n \nThe clinic to be acquired will establish HOPE's model for clinics operating in the Company's network across the country, providing the highest standard of care to patients suffering from problems such as suicidal depression, PTSD and other CNS disorders. These treatments may include Ketamine, Spravatoâ, Transcranial Magnetic Stimulation (TMS), talk therapy and other treatment options. Additionally, patients may also have access to clinical trials of new treatment modalities through these clinics.\n\"This clinic is the ideal foundation for Hope's clinic network; the practice provides state-of-the-art treatment for patients dealing with many CNS disorders and has highly efficient operations; these aspects can serve as a model for future clinics entering our network,\" said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics. \"Additionally, we look forward to working with the founder as our CMIO, as we establish HOPE as a model for clinics that aim to provide the latest standard of care treatments for CNS healthcare providers nationwide.\"\nAbout HOPE Therapeutics, Inc.\nHOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform d...